Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There…
